The Human Variable 

Infection-associated chronic conditions (IACCs), including Long COVID, ME/CFS, post-treatment Lyme disease syndrome (PTLDS), and related post-infectious syndromes, present a persistent challenge to conventional medical workflows. These conditions are multi-system, fluctuating, and temporally delayed, with symptom expression shaped by environmental exposures, autonomic regulation, immune reactivity, hormonal state, and cumulative demand.

Climate change is accelerating fungal evolution at the same moment millions of Americans are living with post-COVID immune instability. This white paper introduces CYNAERA’s national fungal-intelligence architecture, integrating climate analytics, immune-terrain modeling, wastewater genomics, micro-clinic stabilization, and antifungal combination logic. It explains why fungal threats are rising, how existing federal infrastructure can be repurposed immediately and what the Un

Innovative Orthostatic Intolerance & POTS Detection for Faster Diagnosis. Orthostatic intolerance and POTS are increasingly more common, disabling, and often missed until someone reads the chart as a timeline. The signs of these conditions already lives in routine positions and vitals clinicians collect anyway: triage after upright waiting, first supine on the bed, a short bathroom walk and return, and discharge.

Developed through over 40 failed trial reconstructions of 20+ conditions, SPARC™ decodes clinical heterogeneity using patient-derived intelligence and CYNAERA’s AI-integrated logic stacks. Each failed trial costs between $20–40 million, and in rare or stigmatized conditions, these failures permanently deter further investment. Most failed trials didn’t fail because the drug was weak. They failed because the patient groups were misread.

STAIR is a structured method for helping hypersensitive patients safely prepare for new exposures: medications, supplements, clinical trials, or even food reintroductions. It’s designed specifically for bodies that traditional medicine excludes, the “too sensitive,” the “too complex,” the “we don’t know what to do with you.”

Contrary to the conventional framing of remission as spontaneous or unachievable, this framework presents remission as a predictable biological outcome, emerging from synchronized interventions across immune, hormonal, mitochondrial, and environmental axes. The CYNAERA Remission Pathway™ outlines a five-phase stabilization and recovery model, while the STAIR: Stable Method™ offers pre-intervention protection for hypersensitive subgroups, including those with mast cell reacti